The EuroPCR 2026 Closing Ceremony marks the conclusion of this premier cardiology event, celebrating the latest advances and achievements in interventional cardiology. It offers an opportunity to reflect on the educational sessions, network with peers, and recognize outstanding contributions to the field.

Welcome to EuroPCR 2026, the premier event for interventional cardiology professionals. This edition offers cutting-edge scientific presentations, live cases, and interactive sessions designed to advance knowledge and clinical practice in cardiovascular interventions.

This session addresses the challenges of managing difficult coronary anatomy in STEMI patients through a series of complex case studies. Topics include management of aneurysms, rare aorto-ostial lesions, thrombosis interplay, PPCI in dextrocardia situs inversus, and hybrid PCI approaches for multifaceted coronary issues.

This session delves into the expansive role of pharmacology in interventional cardiology, addressing topics ranging from coronary atherostenosis to radial artery management. Key discussions include the real-world efficacy and safety of intravenous cangrelor-assisted PCI in chronic coronary syndromes, comparative analysis of intra-arterial verapamil versus placebo for...

Elad Asher reviews the EROSION III trial, presented by Haibo Jia, which studied whether OCT guidance compared with angiographic guidance only is associated with lower stent rate implantation during pPCI in STEMI patients with non-obstructive stenosis.

Nicola Ryan provides her take on the BEST trial which was presented by Jung-Min Ahn at TCT 2022.

It is a randomised, multicentre, non-inferiority trial comparing PCI with second-generation everolimus-eluting stents and CABG in patients with non-left main multivessel coronary artery disease. At two-year follow-up PCI was shown...

Pierre Deharo and Giuseppe Di Gioia provide their take on this analysis of the 5 years incidence, outcomes and predictors of hemodynamic SVD in patients undergoing TAVI and surgery from the Corevalve US Pivotal and SURTAVI trials.

Ali Nazmi Calik provides a summary and key take-aways and infographics of 9 major trials of interest to interventional cardiologists presented at ACC.21

Kalaivani Mahadevan provides an in-depth analysis of the ORBITA-CTO trial: a first-ever randomised, double-blind, placebo-controlled trial evaluating CTO PCI in stable angina patients.
She also interviewed principal investigators Sarosh Khan and John Davies following the LBCT Scientific Session at ACC.26 in New Orleans and simultaneous publication in...

Nicola Ryan provides her take on the 10-year follow-up of the HOST-EXAM, which was presented by Hyo-Soo Kim at ACC.26 in New Orleans.